← Back to searchRecruitingRecruiting
Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
NCT07449039 · University of California, Los Angeles
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.
Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.
Eligibility criteria
Inclusion Criteria:
* Prenatal care at UCLA Health
* Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
* Confirmed gestational diabetes diagnosis based on 2-step approach
* Maternal age \>= 18 years
Exclusion Criteria:
* Pre-gestational diabetes (T1DM or T2DM)
* Multifetal gestation
* Intra-amniotic infection by clinical criteria
* Postpartum hemorrhage
* Maternal ICU admission
* Known allergy to medical-grade adhesive
* Presence of skin lesions at anticipated CGM application site
* Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
* Metformin use
* Steroid use
* Terbutaline use within 4 hours of delivery
* Cystic fibrosis
* MODY (mature onset of diabetes in the young)
Study design
Enrollment target: 50 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-09-28
Estimated completion: 2030-06
Last updated: 2026-03-04
Interventions
Device: Continuous Glucose Monistor
Primary outcomes
- • Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test (24 hours postpartum and 1-3 months postpartum)
- • Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum (24 hours postpartum and 1-3 months postpartum)
Sponsor
University of California, Los Angeles · other
Contacts & investigators
ContactRujuta Sathe · contact · RSathe@mednet.ucla.edu · 310-794-8893
ContactDana Levin-Lopez, MPH · contact · dlevinlopez@mednet.ucla.edu · 310-794-8893
InvestigatorChristina Han, MD · principal_investigator, University of California, Los Angeles
All locations (1)
University of California, Los AngelesRecruiting
Los Angeles, California, United States